RARA and leukemia: ICC continues to recognize the specific entities of “acute promyelocytic leukemia (APL) with t(15;17) (q24.1;q21.2)/PML::RARA”, “AML with t(9;11) (p21.3;q23.3)/MLLT3::KMT2A”, and “AML with inv(3) (q21.3q26.2) or t(3;3) (q21.3;q26.2)/GATA2; MECOM(EVI1)” as distinct entities; and also recognizes other leukemias with similar biology but driven by variant fusion partners as “APL with other RARA rearrangements”, “AML with other KMT2A rearrangements”, and “AML with other MECOM rearrangements” [3,4].